Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • inderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Följda bolag
    • Teamet
Regulatoriskt pressmeddelande

Optomed Oyj: Composition of Optomed's Nomination Board

Optomed
Läs börsmeddelandet

Optomed Plc Stock Exchange Release 9 September 2025 at 9.30, Helsinki

Composition of Optomed's Nomination Board

According to Optomed's shareholder register of 1st of September 2025, the shareholders represented in the shareholders' Nomination Board are OP-Rahastoyhtiö Oy (OP funds), SP-Rahastoyhtiö Oy (SP Funds) and Danske Invest Rahastoyhtiö Oy (Danske Funds). These shareholders have appointed the following persons to the Nomination Board:

 

  • Vesa Vanha-Honko, OP funds
  • Petteri Vaarnanen, SP funds
  • Ville Kivipelto, Danske Funds


Petri Salonen, Chairman of Optomed's Board of Directors, will serve as the Nomination Board's expert member.

According to the resolution of Optomed General Meeting, the Optomed Nomination Board consists of the representatives of Optomed three largest shareholders as of the first trading day September, and the Chairman of the Board of Directors as an expert member. Should a shareholder not wish to exercise the nomination right, the right shall be transferred to the next largest shareholder who otherwise would not be entitled to nominate a member.

The Nomination Board is to prepare proposals on the composition and members of the Board of Directors and their remuneration for the next Annual General Meeting and it will submit its proposal to the Board of Directors 31 January 2026 at the latest.



Optomed Plc



Further enquiries

Petri Salonen, Chairman of the Board, Optomed Plc, petri.salonen@optomed.com

 

 

Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.